Assessment of the effect of vincristine on the biodistribution of tcm-labelled glucoheptonic acid in female balb/c mice

Nuclear Medicine Communications

Volumn 21, Issue 6, 2000, Pages 557-560

  Mattos, D M M ^a   Gomes, M L ^a   Freitas, R S ^b   Rodrigues, P C ^b   Nascimento, V D ^b   Boasquevisque, E M ^c   Paula, E F ^c   Bernardo filho, M ^c  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Centro de Pesquisa   (Brazil)

^c HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SUGAR ACID; TECHNETIUM COMPLEX; TECHNETIUM TC 99M GLUCEPTATE; VINCRISTINE;

ANIMAL; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; DRUG EFFECT; FEMALE; HEART MUSCLE; KIDNEY; LYMPH NODE; METABOLISM; MOUSE; OVARY; SPLEEN; THYMUS; TISSUE DISTRIBUTION; UTERUS;

ANIMALS; FEMALE; KIDNEY; LYMPH NODES; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MYOCARDIUM; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; OVARY; RADIOPHARMACEUTICALS; SPLEEN; SUGAR ACIDS; THYMUS GLAND; TISSUE DISTRIBUTION; UTERUS; VINCRISTINE;

EID: 0034203614     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200006000-00010     Document Type: Article

References (14)

1. Calabresi P, Chabner A. Chemotherapy of neoplastic diseases. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 1257-1260.
2. Mareel M, De Mets M. Effect of microtubule inhibitors on invasion and on related activities of tumor cells. Int Ver Cytol 1984; 11: 90-125.
3. Salloum E, Schubert RW. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996; 14: 2435-2443.
4. McEvoy GK, McQuarrie GM, DiPietro-Heydorn J. Antineoplastic agents. In: McEvoy GK, ed. Drug information. USA: American Society of Hospital Pharmacists, 1987: 512-514.
5. Saha GB. Normal biodistribution of diagnostic radiopharmaceutical. In: Hladik III WB, Saha GB, Study KT, eds. Essentials of nuclear medicine science. Baltimore, MD: Williams & Wilkins, 1987: 3-19.
6. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Safety 1993; 8: 280-294.
7. Lentle BC, Scott JR. Iatrogenic alterations in radionuclide biodistribution. Sem Nucl Med 1979; 9: 131-143.
8. Owunwanne A. Technetium-99m radiopharmaceuticals. In: Owunwanne A, Patel M, Sadek S, eds. The handbook of radiopharmaceuticals. London: Chapman & Hall, 1995; 57-99.
9. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med 1994; 21: 348-356.
10. m-DTPA in balb/c mice. J Exp Clin Res 1998; 17: 313-316.
11. Gomes ML, Braga ACS, Mattos DMM, Freitas RS, Boasquevisque EM, Bernardo-Filho M. Mitomycin-c effect on the biodistribution of the radiopharmaceutical technetium-99m methylenediphosphonic acid in Balb/c mice. Nucl Med Commun 1998; 19: 1177-1179.
12. Hung JC, Ponto JA, Hammes RJ. Radiopharmaceutical-related pitfalls and artifacts. Sem Nucl Med 1996; 26: 208-255.
13. Lutrin CL, McDougall IR, Goris MI. Intense concentration of Tc-99m pyrophosphate in kidneys of children treated with chemotherapeutic drugs for malignant diseases. Radiology 1978; 128: 165-167.
14. Beckerman C, Pavel DG, Bitran U, Ryo Y, Pinsky S. The effects of inadvertent administration of antineoplastic agents prior to Ga-67 injection: Concise communication. J Nucl Med 1984; 25: 430-435.